Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 Merck known as MSD outside the United States …
Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial
KEYTRUDA
® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells.
1
An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily.